Zobrazeno 1 - 10
of 58
pro vyhledávání: '"Mitchell B Diccianni"'
Publikováno v:
PLoS ONE, Vol 15, Iss 7, p e0236115 (2020)
BackgroundAnti-GD2 therapy with dinutuximab is effective in improving the survival of high-risk neuroblastoma patients in remission and after relapse. However, allodynia is the major dose-limiting side effect, hindering its use for neuroblastoma pati
Externí odkaz:
https://doaj.org/article/5de29d060d224f6c912d99ee93ba3577
Autor:
Richard T Williams, Lisa M Barnhill, Huan-Hsien Kuo, Wen-Der Lin, Ayse Batova, Alice L Yu, Mitchell B Diccianni
Publikováno v:
PLoS ONE, Vol 9, Iss 2, p e88219 (2014)
The INK4A locus codes for two independent tumor suppressors, p14ARF and p16/CDKN2A, and is frequently mutated in many cancers. Here we report a novel deletion/substitution from CC to T in the shared exon 2 of p14ARF/p16 in a melanoma cell line. This
Externí odkaz:
https://doaj.org/article/7525970b81d64aeaa0ac840df7da95c6
Autor:
Mickaël Terme, Mylène Dorvillius, Denis Cochonneau, Tanguy Chaumette, Wenhua Xiao, Mitchell B Diccianni, Jacques Barbet, Alice L Yu, François Paris, Linda S Sorkin, Stéphane Birklé
Publikováno v:
PLoS ONE, Vol 9, Iss 2, p e87210 (2014)
Anti-GD2 antibody is a proven therapy for GD2-positive neuroblastoma. Monoclonal antibodies against GD2, such as chimeric mAb ch14.18, have become benchmarks for neuroblastoma therapies. Pain, however, can limit immunotherapy with anti-GD2 therapeuti
Externí odkaz:
https://doaj.org/article/3b49ad6202ac4463bff6f98234611e69
Autor:
Paul M. Sondel, Alice L. Yu, Andrew L. Gilman, M. Fevzi Ozkaynak, Julie R. Park, John M. Maris, Michael D. Hogarty, Susan L. Cohn, Katherine K. Matthay, Stephen D. Gillies, Ralph A. Reisfeld, Mitchell B. Diccianni, Jacquelyn A. Hank, Arlene Naranjo, Wendy B. London, Patrick K. Reville, Dustin Hess, Yiqiang Song, Eneida A. Mendonça, KyungMann Kim, Lakeesha Carmichael, Wei Wang, Amy K. Erbe
Supplementary Methods and Supplementary Table Legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b69d4cac1b9a2be587c851224387691
https://doi.org/10.1158/1078-0432.22463705
https://doi.org/10.1158/1078-0432.22463705
Autor:
Paul M. Sondel, Alice L. Yu, Andrew L. Gilman, M. Fevzi Ozkaynak, Julie R. Park, John M. Maris, Michael D. Hogarty, Susan L. Cohn, Katherine K. Matthay, Stephen D. Gillies, Ralph A. Reisfeld, Mitchell B. Diccianni, Jacquelyn A. Hank, Arlene Naranjo, Wendy B. London, Patrick K. Reville, Dustin Hess, Yiqiang Song, Eneida A. Mendonça, KyungMann Kim, Lakeesha Carmichael, Wei Wang, Amy K. Erbe
Purpose: In 2010, a Children's Oncology Group (COG) phase III randomized trial for patients with high-risk neuroblastoma (ANBL0032) demonstrated improved event-free survival (EFS) and overall survival (OS) following treatment with an immunotherapy re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::926f56ed51054308532a63e87b3333d2
https://doi.org/10.1158/1078-0432.c.6525485
https://doi.org/10.1158/1078-0432.c.6525485
Autor:
Paul M. Sondel, Alice L. Yu, Andrew L. Gilman, M. Fevzi Ozkaynak, Julie R. Park, John M. Maris, Michael D. Hogarty, Susan L. Cohn, Katherine K. Matthay, Stephen D. Gillies, Ralph A. Reisfeld, Mitchell B. Diccianni, Jacquelyn A. Hank, Arlene Naranjo, Wendy B. London, Patrick K. Reville, Dustin Hess, Yiqiang Song, Eneida A. Mendonça, KyungMann Kim, Lakeesha Carmichael, Wei Wang, Amy K. Erbe
Clinical characteristics of COG patients, according to treatment group, for all patients and for those genotyped for KIR/KIR-ligand.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a5bb83a24d9f4c6d3d04489706900e7
https://doi.org/10.1158/1078-0432.22463687
https://doi.org/10.1158/1078-0432.22463687
Autor:
Paul M. Sondel, Julie R. Park, Rochelle Bagatell, John M. Maris, Susan L. Cohn, Katherine K. Matthay, Marguerite Parisi, Barry L. Shulkin, Malcolm Smith, Sheena C. Tenney, Wendy B. London, Ayse Batova, Jacquelyn A. Hank, Jacek Gan, Mitchell B. Diccianni, Arlene Naranjo, M. Fevzi Ozkaynak, Andrew L. Gilman, Alice L. Yu
Figure S1a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f0ff0ee0abecf0b93a4f3cba17f4438
https://doi.org/10.1158/1078-0432.22484007.v1
https://doi.org/10.1158/1078-0432.22484007.v1
Autor:
Paul M. Sondel, Julie R. Park, Rochelle Bagatell, John M. Maris, Susan L. Cohn, Katherine K. Matthay, Marguerite Parisi, Barry L. Shulkin, Malcolm Smith, Sheena C. Tenney, Wendy B. London, Ayse Batova, Jacquelyn A. Hank, Jacek Gan, Mitchell B. Diccianni, Arlene Naranjo, M. Fevzi Ozkaynak, Andrew L. Gilman, Alice L. Yu
Figure S1a, Figure S1b; Supplementary Tables S1-S7
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d54eeb58ba43ac859d741380368f48f8
https://doi.org/10.1158/1078-0432.22484001
https://doi.org/10.1158/1078-0432.22484001
Autor:
Paul M. Sondel, Julie R. Park, Rochelle Bagatell, John M. Maris, Susan L. Cohn, Katherine K. Matthay, Marguerite Parisi, Barry L. Shulkin, Malcolm Smith, Sheena C. Tenney, Wendy B. London, Ayse Batova, Jacquelyn A. Hank, Jacek Gan, Mitchell B. Diccianni, Arlene Naranjo, M. Fevzi Ozkaynak, Andrew L. Gilman, Alice L. Yu
Purpose:Previously our randomized phase III trial demonstrated that immunotherapy including dinutuximab, a chimeric anti-GD2 mAb, GM-CSF, and IL2 improved survival for children with high-risk neuroblastoma that had responded to induction and consolid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::22aa2cb454ff0cd5cf051e4572a0bff8
https://doi.org/10.1158/1078-0432.c.6531294
https://doi.org/10.1158/1078-0432.c.6531294
Autor:
Mitchell B. Diccianni, Alice L. Yu, Lei Bao, Minya Pu, Karen Messer, Jenna A. Mielke, Ayse Batova, Youngjin Kim, Olga Cohen, Richard T. Williams, Lisa M. Barnhill
CAI2, p16 and ARF expression in normal tissue compared to levels in fibroblasts (Supp Figure S1); Growth comparison of low vs. high passage NMB7 cells (Supp Figure S2); Growth comparison of low vs. high passage NMB7 cells in the absence of serum or p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5fe769e2bc50ac999aa27a1368a1ec3b
https://doi.org/10.1158/0008-5472.22404552
https://doi.org/10.1158/0008-5472.22404552